Chargement en cours...
Changes in Skeletal Tumor Activity on (18)F-choline PET/CT in Patients Receiving (223)Radium Radionuclide Therapy for Metastatic Prostate Cancer
Radium-223 dichloride is an alpha-emitting radiopharmaceutical shown to prolong survival in patients with castrate-resistant prostate cancer (CRPC) and symptomatic skeletal metastases. This report describes in two patients the acute changes in bone metastatic activity detected by F-18 choline PET/CT...
Enregistré dans:
| Publié dans: | Nucl Med Mol Imaging |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer Berlin Heidelberg
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4463874/ https://ncbi.nlm.nih.gov/pubmed/26082811 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13139-014-0314-0 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|